{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-069494","form_type":"8-K","ticker":"HOTH","cik":"0001711786","company_name":"Hoth Therapeutics, Inc.","filed_at":"2023-08-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.950355+00:00","generated_at":"2026-06-11T06:19:40.633535+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Hoth Therapeutics shareholders re-elect all five directors, approve auditor and equity plan at 2023 annual meeting","bullets":["All five nominees (Robb Knie, David Sarnoff, Graig Springer, Wayne Linsley, Jeff Pavell) elected to board with large majority of votes cast.","Ratification of Withum Smith+Brown as independent auditor for FY2023 approved: 1,111,058 for, 158,230 against, 54,787 abstain.","Hoth Therapeutics Amended and Restated 2022 Omnibus Equity Incentive Plan approved: 190,903 for, 112,224 against, 27,459 abstain, 993,489 broker non-votes.","Total shares voted: 1,324,075, representing a quorum."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-069494","json":"https://secwatch.observer/filing/0001213900-23-069494.json","markdown":"https://secwatch.observer/filing/0001213900-23-069494.md","text":"https://secwatch.observer/filing/0001213900-23-069494.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711786/000121390023069494/0001213900-23-069494-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711786/000121390023069494/ea183965-8k_hoththera.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T06:19:40.633535+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4ab9cbc0cd6043d2a1b671a279d799a70322150a","claim":"Hoth Therapeutics, Inc. shareholders approved Election of five directors to serve until the next annual meeting at the 2023-08-18 meeting.","evidence_excerpt":"All of the five nominees for director were elected to serve until the next annual meeting of shareholders or until their respective successors have been duly elected and qualified, or until such director’s earlier resignation, removal or death. The result of the votes to elect the five directors were as follows: Directors For Against Abstentions Broker Non-Votes Robb Knie 220,147 58,177 52,262 993,489 David Sarnoff 217,637 57,613 55,336 993,489 Graig Springer 199,778 78,545 52,263 993,489 Wayne Linsley 207,197 70,970 52,419 993,489 Jeff Pavell 213,588 63,044 53,954 993,489","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1711786/000121390023069494/0001213900-23-069494-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-08-18"}],"fact_type":"shareholder_vote"},{"claim_id":"51ae420661a18b83171ac0fb921d029661755c51","claim":"Hoth Therapeutics, Inc. shareholders approved Ratification of appointment of Withum Smith+Brown, PC as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-08-18 meeting.","evidence_excerpt":"The shareholders approved the ratification of the appointment of Withum as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The result of the votes to approve Withum was as follows: For Against Abstain 1,111,058 158,230 54,787","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1711786/000121390023069494/0001213900-23-069494-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-08-18"}],"fact_type":"shareholder_vote"},{"claim_id":"75b5d2c8b412125970115022e8e869f9d11ba4fd","claim":"Hoth Therapeutics, Inc. shareholders approved Approval of Hoth Therapeutics, Inc. Amended and Restated 2022 Omnibus Equity Incentive Plan at the 2023-08-18 meeting.","evidence_excerpt":"The shareholders approved the Amended and Restated 2022 Plan. The result of the votes to approve the Amended and Restated 2022 Plan was as follows: For Against Abstain Broker Non-Votes 190,903 112,224 27,459 993,489","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1711786/000121390023069494/0001213900-23-069494-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-08-18"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}